Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment

The Multiple Myeloma Research Foundation and Astellas Pharma Global Development, Inc. today announced that they have entered into a joint collaboration for the clinical development of OSI-906 in patients with relapsed multiple myeloma.

6 May 2011

FDA approves Novartis' Afinitor tablets for pancreatic NET treatment

Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration approved Afinitor tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin in patients with unresectable, locally advanced or metastatic disease.

6 May 2011

CytRx reports $6.3 million net loss for first quarter 2011

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months ended March 31, 2011, and provided a business update.

5 May 2011

Acorda reports $0.7 million GAAP net loss for first quarter 2011

Acorda Therapeutics, Inc. today announced its financial results for the first quarter ended March 31, 2011.

5 May 2011

ArQule reports net loss of $1,466,000 for first quarter 2011

ArQule, Inc. today announced its financial results for the first quarter of 2011.

5 May 2011

ZIOPHARM reports net loss of $39.0 million for first quarter 2011

ZIOPHARM Oncology, Inc, an oncology small molecule and synthetic biology drug development company, today reported its financial results for the three months ended March 31, 2011, and provided an update on the Company's activities in the first quarter.

5 May 2011

Theragenics reports consolidated revenue of $20.3 million for first quarter 2011

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the first quarter ended March 31, 2011.

5 May 2011

Over 1000 patients enrolled in world's largest ever pancreatic cancer vaccine trial

KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that it had been officially notified by the independent Data Monitoring Committee that over 1000 patients have been enrolled in the TeloVac Study, making it the world's largest ever pancreatic cancer vaccine trial.

5 May 2011

S*BIO regains North American, European rights to novel JAK2 inhibitors from Onyx

S*BIO Pte Ltd today announced the restructuring of its collaboration and option agreement with Onyx Pharmaceuticals, which was entered into in January 2009.

5 May 2011

Research experts to speak at brain tumor educational conference

Patients, families and caregivers are invited to attend an educational conference covering many aspects of brain tumors May 14 at Cedars-Sinai Medical Center.

5 May 2011

Thomas Jefferson University receives award to develop novel radiation drugs

Shortly before Japan's devastating nuclear incident, researchers at Thomas Jefferson University and Hospitals received an award to find novel drugs to treat people exposed to dangerous amounts of radiation in the wake of a nuclear terrorist attack or a nuclear accident.

5 May 2011

TGen licenses ONCO-101 cancer drug to Syracuse

The Translational Genomics Research Institute has licensed its first drug, a unique compound that targets cancer tumors by modifying the actions of proteins.

5 May 2011

Yale, Debiopharm partner to develop and commercialize Debio 1036 for inflammatory diseases

Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Yale University, a premier university with a long tradition of both basic and clinically directed biomedical research, announce an exclusive worldwide license agreement concerning the development and commercialization of Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory diseases.

4 May 2011

ChipDX identifies gene expression signature in early-stage breast tumors

ChipDX LLC, a New York-based molecular diagnostics and personalized medicine research company, has discovered a gene expression signature present in the cells of early-stage breast tumors that indicates the chance of the tumor recurring within 10 years.

4 May 2011

FibroGen announces proof-of-principle for FG-4592 Phase 2 study in hemodialysis patients

FibroGen, Inc., today announced proof-of-principle for oral anemia therapy FG-4592, a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, in end-stage renal disease patients receiving hemodialysis.

4 May 2011

Cancers use body's own defences to resist drugs

CANCER RESEARCH UK scientists have discovered that tumours are able to recruit part of the body's defence system to protect them from the effect of a drug designed to block the supply of blood to the tumour.

4 May 2011

Top-line results from Lymphoseek NEO3-09 Phase 3 study in breast cancer, melanoma

Neoprobe Corporation, a diversified developer of innovative oncology diagnostic products, today announced top-line results from its Lymphoseek NEO3-09 study.

4 May 2011

WWP2 protein appears to play a key role in tumor survival

A protein known as WWP2 appears to play a key role in tumor survival, a research team headed by a scientist at The University of Texas MD Anderson Cancer Center reports in an advance online publication of Nature Cell Biology.

4 May 2011

CTI to re-submit pixantrone NDA to FDA's Office of New Drugs for re-review

Cell Therapeutics, today announced that the Office of New Drugs of the U.S. Food and Drug Administration after carefully reviewing the materials CTI submitted in support of its appeal, the reviews of the New Drug Application for pixantrone prepared by the FDA staff, the transcript of the March 22, 2010 Oncology Drugs Advisory Committee meeting and consulting with the Center for Drug Evaluation and Research's Deputy Director of Clinical Science and the Office of Biostatistics, concluded that accelerated approval of pixantrone NDA 022481 may not necessarily be out of reach based on a single controlled clinical trial, provided two key matters can be satisfactorily resolved.

3 May 2011

Astex earns GBP5.9 M milestone payment from GSK for fragment-based screening platform

Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, announced that it has achieved multiple early milestones in its fragment-based drug discovery collaboration with GlaxoSmithKline which commenced in November 2009.

3 May 2011

Oncology News and Research

Further Reading

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment

FDA approves Novartis' Afinitor tablets for pancreatic NET treatment

CytRx reports $6.3 million net loss for first quarter 2011

Acorda reports $0.7 million GAAP net loss for first quarter 2011

ArQule reports net loss of $1,466,000 for first quarter 2011

ZIOPHARM reports net loss of $39.0 million for first quarter 2011

Theragenics reports consolidated revenue of $20.3 million for first quarter 2011

Over 1000 patients enrolled in world's largest ever pancreatic cancer vaccine trial

S*BIO regains North American, European rights to novel JAK2 inhibitors from Onyx

Research experts to speak at brain tumor educational conference

Thomas Jefferson University receives award to develop novel radiation drugs

TGen licenses ONCO-101 cancer drug to Syracuse

Yale, Debiopharm partner to develop and commercialize Debio 1036 for inflammatory diseases

ChipDX identifies gene expression signature in early-stage breast tumors

FibroGen announces proof-of-principle for FG-4592 Phase 2 study in hemodialysis patients

Cancers use body's own defences to resist drugs

Top-line results from Lymphoseek NEO3-09 Phase 3 study in breast cancer, melanoma

WWP2 protein appears to play a key role in tumor survival

CTI to re-submit pixantrone NDA to FDA's Office of New Drugs for re-review

Astex earns GBP5.9 M milestone payment from GSK for fragment-based screening platform

A best-practice guide for laboratory services in oncology trials eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News